News

Galecto Reports First Quarter 2025 Operating and Financial Results
Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for ...
Nasdaq6d
Galecto, Inc. Reports First Quarter 2025 Financial Results and Progress on AML Treatment Development
Galecto, Inc. announced its financial results for Q1 2025, highlighting continued progress on its dual ENL-YEATS and FLT3 inhibitor, GB3226, aimed at treating acute myeloid leukemia (AML).
manilatimes7mon
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines
Galecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211 Bolsters pipeline by obtaining global rights to BRM-1420, a novel dual ENL-YEATS and FLT3 inhibitor for ...
Galecto, Inc.: Galecto Reports First Quarter 2025 Operating and Financial Results
Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced ...